StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ANVSAnnovis Bio, Inc.
stockpulse.co.kr
NYSE
$1.02▲ 2.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $35.3MShares out 34.6M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

6
  • 5d agoPre-market26.10.20 08:49filed
    8-KKey event#●●●

    Annovis Bio, Inc.

    Annovis Bio filed this report to correct a typographical error regarding audit fees disclosed in the proxy statement for its annual meeting of stockholders held on June 17, 2026. The corrected total audit fees are $515,000 for 2025 and $482,045 for 2024.…more

    $1.02+2.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.15Regular26.10.16 01:34
    SCHEDULE 13G/AOwnership

    Annovis Bio, Inc.

    Empery Asset Management, LP has filed a SCHEDULE 13G/A regarding its beneficial ownership in Annovis Bio, Inc. The filing serves as an update to the reporting entity's equity position in the company.…more

    $1.02+2.00%vs prev close
    View filingShare
  • 10.7Regular26.10.07 22:38
    DEFA14AOther

    Annovis Bio, Inc.

    Annovis Bio has rescheduled its Special Meeting of Stockholders from October 14, 2026, to November 3, 2026. The company has amended Proposal No. 1 to increase authorized common stock from 70 million to 140 million shares, with the approval threshold updated to a majority of votes cast rather than a majority of outstanding shares, while withdrawing the proposal to increase authorized preferred stock. Brokers now have discretionary authority to vote on this proposal.…more

    $1.02+2.00%vs prev close
    View filingShare

5 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.23Pre-market26.09.23 21:01
    #●●●#●●●#●●●

    Annovis Bio Announces Collaboration With Weave Bio On Buntanetap NDA; Phase 3 Data Expected March 2027…more

    Annovis Bio has entered into a collaboration with Weave Bio to support the New Drug Application (NDA) for Buntanetap. The company expects to release topline data from its Phase 3 Alzheimer's clinical trial in March 2027.…more

    $1.02+2.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 8.14Pre-market26.08.14 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    Annovis Bio has successfully completed patient enrollment for its Phase 3 Alzheimer’s disease trial, exceeding initial targets. The company remains on track for topline data results in the first quarter of 2027 while continuing its Parkinson’s disease clinical studies.…more

    $1.02+2.00%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →